JOP20230315A1 - مركبات الإندول المستبدلة وطرق استخدامها - Google Patents
مركبات الإندول المستبدلة وطرق استخدامهاInfo
- Publication number
- JOP20230315A1 JOP20230315A1 JOJO/P/2023/0315A JOP20230315A JOP20230315A1 JO P20230315 A1 JOP20230315 A1 JO P20230315A1 JO P20230315 A JOP20230315 A JO P20230315A JO P20230315 A1 JOP20230315 A1 JO P20230315A1
- Authority
- JO
- Jordan
- Prior art keywords
- compounds
- indole
- substitutes
- inhibitors
- alternative pathway
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Ophthalmology & Optometry (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163196339P | 2021-06-03 | 2021-06-03 | |
| US202163290019P | 2021-12-15 | 2021-12-15 | |
| US202263346120P | 2022-05-26 | 2022-05-26 | |
| PCT/US2022/032042 WO2022256586A2 (en) | 2021-06-03 | 2022-06-03 | Substituted indole compounds and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JOP20230315A1 true JOP20230315A1 (ar) | 2023-11-30 |
Family
ID=84323595
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JOJO/P/2023/0315A JOP20230315A1 (ar) | 2021-06-03 | 2023-11-30 | مركبات الإندول المستبدلة وطرق استخدامها |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US20240287034A1 (enExample) |
| EP (1) | EP4346812A4 (enExample) |
| JP (1) | JP7895996B2 (enExample) |
| KR (1) | KR20240017004A (enExample) |
| CN (1) | CN120081822A (enExample) |
| AU (1) | AU2022283903A1 (enExample) |
| BR (1) | BR112023025235A2 (enExample) |
| CA (1) | CA3222144A1 (enExample) |
| CL (1) | CL2023003591A1 (enExample) |
| CO (1) | CO2023016557A2 (enExample) |
| CR (1) | CR20230564A (enExample) |
| DO (1) | DOP2023000263A (enExample) |
| EC (1) | ECSP23090260A (enExample) |
| IL (1) | IL308835A (enExample) |
| JO (1) | JOP20230315A1 (enExample) |
| MX (1) | MX2023014274A (enExample) |
| PE (1) | PE20250114A1 (enExample) |
| PH (1) | PH12023553130A1 (enExample) |
| WO (1) | WO2022256586A2 (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20230049115A (ko) * | 2020-08-07 | 2023-04-12 | 상하이 메이유에 바이오테크 디벨롭먼트 컴퍼니 리미티드 | 보체 인자 b 억제제 및 이의 약학적 조성물, 제조 방법 및 용도 |
| US20240109861A1 (en) * | 2020-12-30 | 2024-04-04 | Medshine Discovery Inc. | Series of piperidine-substituted benzoic acid compounds, and use thereof |
| WO2023278698A1 (en) * | 2021-06-30 | 2023-01-05 | Apellis Pharmaceuticals, Inc. | Complement inhibition |
| CN118043314A (zh) | 2021-08-18 | 2024-05-14 | 西藏海思科制药有限公司 | 一种苯并氮杂芳环衍生物及其在医药上的应用 |
| AU2022376760A1 (en) * | 2021-10-27 | 2024-05-02 | Hansoh Bio Llc | Piperidinyl indole derivatives, preparation methods and medicinal uses thereof |
| PE20242005A1 (es) * | 2022-01-24 | 2024-10-03 | Novartis Ag | Derivados espirociclicos de piperidinilo como inhibidores del factor b del complemento y usos de los mismos |
| WO2023237012A1 (zh) * | 2022-06-07 | 2023-12-14 | 正大天晴药业集团股份有限公司 | 双环取代的芳香羧酸类氘代化合物 |
| CN119698414A (zh) * | 2022-06-20 | 2025-03-25 | 深圳信立泰药业股份有限公司 | 一种吲哚-苯基哌啶化合物及其制备方法与应用 |
| CN119546585A (zh) * | 2022-06-23 | 2025-02-28 | 上海济煜医药科技有限公司 | 吲哚化合物的制备、应用及用途 |
| TW202423426A (zh) * | 2022-08-31 | 2024-06-16 | 美商奇努克醫療股份有限公司 | 經取代之吲哚化合物及其使用方法 |
| JP2025530222A (ja) * | 2022-09-10 | 2025-09-11 | 江▲蘇▼豪森▲薬▼▲業▼集▲団▼有限公司 | ２－置換ピペリジン誘導体、その製造方法及び医薬的用途 |
| US20260159497A1 (en) * | 2022-11-14 | 2026-06-11 | Novartis Pharma Ag | Solid forms of a complement factor b inhibitor |
| CN120303261A (zh) * | 2022-11-29 | 2025-07-11 | 上海济煜医药科技有限公司 | 苯并螺环吲哚化合物的制备、应用及用途 |
| WO2024148274A1 (en) * | 2023-01-05 | 2024-07-11 | Apellis Pharmaceuticals, Inc. | Complement inhibition |
| EP4650351A1 (en) * | 2023-01-09 | 2025-11-19 | Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd. | Inhibitor of complement factor b |
| JP2026506078A (ja) * | 2023-02-16 | 2026-02-20 | ハイスーク ファーマシューティカル グループ カンパニー リミテッド | ベンゾアザ芳香環誘導体の塩、結晶形及びその医薬的応用 |
| TW202434240A (zh) * | 2023-02-22 | 2024-09-01 | 大陸商西藏海思科製藥有限公司 | 苯並氮雜芳環衍生物的藥物組合物及其在醫藥上的應用 |
| AU2024261191A1 (en) * | 2023-04-27 | 2025-11-06 | Jiangsu Hansoh Pharmaceutical Group Co., Ltd. | Salt of piperidylindole compound and preparation method therefor |
| EP4739390A1 (en) | 2023-07-04 | 2026-05-13 | Sitala Bio Ltd | 2-(1h-indol-4-yl)methyl)2h-indazole derivatives as factor b inhibitors |
| CN121752557A (zh) | 2023-07-04 | 2026-03-27 | 希塔拉生物有限公司 | 2-(1h-吲哚-4-基)甲基)-异吲哚啉衍生物作为因子b抑制剂 |
| WO2025008516A2 (en) | 2023-07-06 | 2025-01-09 | Sitala Bio Ltd | Novel compounds |
| WO2025008517A1 (en) | 2023-07-06 | 2025-01-09 | Sitala Bio Ltd | Indole derivatives with factor b inhibitory activity |
| CN119371402A (zh) * | 2023-07-26 | 2025-01-28 | 上海美悦生物科技发展有限公司 | 螺环烯基类或氮杂烯基类化合物及其药物组合物、制备方法和用途 |
| TW202517258A (zh) * | 2023-09-20 | 2025-05-01 | 大陸商上海美悦生物科技發展有限公司 | 雜環化合物在製備預防和／或治療腎臟疾病的藥物中的用途 |
| CN122396492A (zh) * | 2023-12-05 | 2026-07-14 | 西藏海思科制药有限公司 | 苯并氮杂芳环衍生物在治疗补体因子b介导的疾病中的用途 |
| WO2025172535A1 (en) | 2024-02-15 | 2025-08-21 | Sitala Bio Ltd | Indole and benzimidazole compounds as factor b inhibitors |
| WO2025256647A1 (zh) * | 2024-06-14 | 2025-12-18 | 润尔眼科药物（广州）有限公司 | 化合物及其医药用途 |
| WO2026008073A1 (zh) * | 2024-07-05 | 2026-01-08 | 南京正大天晴制药有限公司 | 补体因子b抑制剂的剂量组合物 |
| WO2026069246A1 (en) * | 2024-09-30 | 2026-04-02 | Novartis Ag | Complement factor b inhibitors and uses thereof |
| CN121949280A (zh) * | 2024-10-31 | 2026-05-01 | 甫康（上海）健康科技有限责任公司 | 一种多取代吲哚类化合物及其制备方法和用途 |
| GB202500206D0 (en) | 2025-01-08 | 2025-02-19 | Sitala Bio Ltd | Novel compounds |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201406973PA (en) * | 2012-05-04 | 2014-12-30 | Novartis Ag | Complement pathway modulators and uses thereof |
| CN104619698B (zh) * | 2012-06-28 | 2016-08-31 | 诺华股份有限公司 | 吡咯烷衍生物及其作为补体途径调节剂的用途 |
| JO3425B1 (ar) * | 2013-07-15 | 2019-10-20 | Novartis Ag | مشتقات البابيريدينيل-اندول واستخدامها كعامل متمم لمثبطات b |
| MX2018016046A (es) * | 2016-06-27 | 2019-05-02 | Achillion Pharmaceuticals Inc | Quinazolina y compuestos indol para tratar trastornos medicos. |
| KR20230049115A (ko) | 2020-08-07 | 2023-04-12 | 상하이 메이유에 바이오테크 디벨롭먼트 컴퍼니 리미티드 | 보체 인자 b 억제제 및 이의 약학적 조성물, 제조 방법 및 용도 |
| WO2022254362A1 (en) | 2021-06-03 | 2022-12-08 | Novartis Ag | 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and medical uses thereof |
| CN117412955A (zh) | 2021-06-03 | 2024-01-16 | 阿尔比里奥公司 | 苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途 |
| KR20240024926A (ko) | 2021-06-24 | 2024-02-26 | 신젠타 크롭 프로텍션 아게 | 살충제로서의 2-[3-[1[(퀴나졸린-4-일)아미노]에틸]피라진-2-일]티아졸-5-카르보니트릴 유도체 및 유사한 화합물 |
| WO2023283256A1 (en) | 2021-07-09 | 2023-01-12 | Aligos Therapeutics, Inc. | Anti-viral compounds |
| MX2024001269A (es) | 2021-07-26 | 2024-04-23 | Harvard College | Inhibidores de rock2 y sus usos. |
| AU2022376760A1 (en) * | 2021-10-27 | 2024-05-02 | Hansoh Bio Llc | Piperidinyl indole derivatives, preparation methods and medicinal uses thereof |
| AR127922A1 (es) | 2021-12-15 | 2024-03-13 | Syngenta Crop Protection Ag | Derivados heterocíclicos bicíclicos microbiocidas |
| US20250326757A1 (en) | 2022-05-26 | 2025-10-23 | Astrazeneca Ab | Solid forms of heterocyclylamides as irak4 inhibitors |
-
2022
- 2022-06-03 PE PE2023003178A patent/PE20250114A1/es unknown
- 2022-06-03 KR KR1020237045081A patent/KR20240017004A/ko active Pending
- 2022-06-03 PH PH1/2023/553130A patent/PH12023553130A1/en unknown
- 2022-06-03 JP JP2023574119A patent/JP7895996B2/ja active Active
- 2022-06-03 CA CA3222144A patent/CA3222144A1/en active Pending
- 2022-06-03 IL IL308835A patent/IL308835A/en unknown
- 2022-06-03 BR BR112023025235A patent/BR112023025235A2/pt unknown
- 2022-06-03 WO PCT/US2022/032042 patent/WO2022256586A2/en not_active Ceased
- 2022-06-03 AU AU2022283903A patent/AU2022283903A1/en active Pending
- 2022-06-03 CR CR20230564A patent/CR20230564A/es unknown
- 2022-06-03 MX MX2023014274A patent/MX2023014274A/es unknown
- 2022-06-03 US US18/566,259 patent/US20240287034A1/en active Pending
- 2022-06-03 CN CN202510248844.6A patent/CN120081822A/zh active Pending
- 2022-06-03 EP EP22816892.8A patent/EP4346812A4/en active Pending
-
2023
- 2023-11-30 EC ECSENADI202390260A patent/ECSP23090260A/es unknown
- 2023-11-30 CL CL2023003591A patent/CL2023003591A1/es unknown
- 2023-11-30 DO DO2023000263A patent/DOP2023000263A/es unknown
- 2023-11-30 CO CONC2023/0016557A patent/CO2023016557A2/es unknown
- 2023-11-30 JO JOJO/P/2023/0315A patent/JOP20230315A1/ar unknown
-
2025
- 2025-05-30 US US19/223,498 patent/US12617774B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| BR112023025235A2 (pt) | 2024-02-27 |
| AU2022283903A1 (en) | 2023-11-30 |
| IL308835A (en) | 2024-01-01 |
| CN120081822A (zh) | 2025-06-03 |
| JP2024521878A (ja) | 2024-06-04 |
| JP7895996B2 (ja) | 2026-07-28 |
| CR20230564A (es) | 2024-02-27 |
| US20240287034A1 (en) | 2024-08-29 |
| WO2022256586A3 (en) | 2023-01-12 |
| PH12023553130A1 (en) | 2024-03-11 |
| ECSP23090260A (es) | 2024-02-29 |
| EP4346812A4 (en) | 2025-04-09 |
| DOP2023000263A (es) | 2024-02-29 |
| MX2023014274A (es) | 2024-04-22 |
| WO2022256586A2 (en) | 2022-12-08 |
| PE20250114A1 (es) | 2025-01-16 |
| CO2023016557A2 (es) | 2024-02-26 |
| CL2023003591A1 (es) | 2024-06-28 |
| US12617774B2 (en) | 2026-05-05 |
| KR20240017004A (ko) | 2024-02-06 |
| US20250289804A1 (en) | 2025-09-18 |
| EP4346812A2 (en) | 2024-04-10 |
| CA3222144A1 (en) | 2022-12-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12023553130A1 (en) | Substituted indole compounds and methods of use thereof | |
| CY1126152T1 (el) | Ενωσεις-αναστολεις της rip1 και μεθοδοι παρασκευης και χρησης αυτων | |
| MX2022016405A (es) | Análogos de nucleósido de 1¿-ciano y usos de estos. | |
| CY1125022T1 (el) | Μεθοδοι για θεραπεια καταστασεων που συνδυαζονται με εξαρτωμενη απο masp-2 ενεργοποιηση συμπληρωματος | |
| CY1117317T1 (el) | Αναστολεις κινασης janus για θεραπεια ξηροφθαλμιας και αλλων σχετικων με τον οφθαλμο ασθενειων | |
| ATE482205T1 (de) | P-38-kinasehemmer | |
| CY1110230T1 (el) | Αναστολεις γυρασης και χρησεις αυτων | |
| ATE356804T1 (de) | Inhibitoren von mitotischem kinesin | |
| EP1537878A4 (en) | IMMUNO-POTENTIAL COMPOSITIONS | |
| CY1107467T1 (el) | Χρηση οξεογονων υδρογονοτροφων στελεχων για την προληψη ή την αγωγη πεπτικων διαταραχων | |
| NO20060871L (no) | Azepinderivater som farmasoytiske midler | |
| BR112023002089A2 (pt) | Compostos de piridazina 6-substituídos como degradadores de smarca2 e/ou smarca4 | |
| ATE548034T1 (de) | Pharmazeutische zusammensetzungen mit droxidopa | |
| HRP20090498T1 (hr) | Kombinacija r,r-glikopirolata, roliprama i budesonida za liječenje upalnih oboljenja | |
| DK1545537T3 (da) | Alfa-7-nikotinreceptoragonister og statiner i kombination | |
| ECSP10010034A (es) | 2-anilinopurin-8-onas como inhibidores de ttk/mps1 para el tratamiento de trastornos proliferativos | |
| CY1110415T1 (el) | Πρωτοτυπα παραγωγα τετραϋδροκαρβαζολιου με βελτιωμενη βιολογικη δραση και βελτιωμενη διαλυτοτητα, ως συνδετες για υποδοχεις συζευγμενους με πρωτεϊνη g (gpcrs) | |
| MX2024009216A (es) | Inhibidores de ectonucleotido pirofosfatasa-fosfodiesterasa 1 (enpp1) y usos de los mismos. | |
| MX2021011289A (es) | Composiciones que comprenden moduladores de isoenzima m2 muscular de piruvato cinasa pkm2 y metodos de tratamiento que usan las mismas. | |
| WO2008021048A3 (en) | Adp-ribosyltransferase based methods and compositions | |
| MX2008008556A (es) | Derivados de triterpenoquinonas y triterpenofenoles y su aplicacion para el tratamiento de tumores y enfermedades parasitarias. | |
| JOP20210009A1 (ar) | طرق لعلاج HFpEF باستعمال داباجليفلوزين وتركيبات تشمله | |
| CR20240023A (es) | Compuestos de sulfonimidamida y usos de los mismos | |
| EA202091736A1 (ru) | Применение колхицина для ингибирования роста опухоли и метастазов | |
| GEAP202416375A (en) | Pro drugs of pde10 compounds |